Skip to main content
SLN logo
SLN
(NASDAQ)
Silence Therapeutics plc
$5.94-- (--)
Loading... - Market loading

Silence Therapeutics (SLN) Balance Sheet

Assets, liabilities, and shareholders' equity with annual and quarterly data.

Silence Therapeutics Balance Sheet Analysis

Assets, liabilities, and stockholders equity in millions GBP

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Silence Therapeutics plc (SLN) - Annual data in millions GBP
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Current Assets
Cash and Cash Equivalents11.28121.3368.7954.8273.5427.4513.5221.4942.75
Short-Term Investments73.8426.000.0016.330.0010.0020.005.040.32
Cash & Short-Term Investments85.11147.3368.7971.1473.5437.4533.5226.5443.06
Accounts Receivable24.6126.910.290.920.3329.310.000.000.00
Inventory0.000.000.000.000.000.000.00-2.45-2.48
Other Current Assets15.2813.1210.3924.6312.479.643.950.520.52
Total Current Assets118.66187.37103.1596.6986.3376.4037.4729.5045.55
Non-Current Assets
Property, Plant & Equipment (Net)1.751.982.672.201.941.130.610.921.17
Long-Term Investments0.000.000.000.280.300.300.28-4.770.00
Goodwill10.629.399.988.017.598.137.698.138.03
Intangible Assets0.290.310.360.320.020.020.030.060.03
Other Non-Current Assets0.133.593.650.000.000.000.005.040.23
Total Non-Current Assets12.7815.2716.3010.819.869.578.619.399.46
Total Assets131.44202.64119.45107.5096.1985.9746.0838.8955.01
Current Liabilities
Accounts Payable4.413.703.353.194.072.291.791.150.46
Short-Term Debt-0.090.120.230.450.140.340.290.000.00
Accrued Liabilities5.758.367.8510.158.858.060.000.000.00
Deferred Revenue0.170.316.570.000.000.000.000.000.00
Other Current Liabilities6.9211.8111.7118.3110.9722.957.582.492.00
Total Current Liabilities13.6116.8222.3421.9415.1725.589.653.832.66
Non-Current Liabilities
Long-Term Debt0.070.000.120.000.000.000.000.000.00
Other Non-Current Liabilities0.000.000.0063.4972.5051.3415.520.000.00
Total Non-Current Liabilities55.5351.7975.1263.4972.5051.3415.521.150.46
Total Liabilities69.1468.6197.4685.4387.6776.9125.173.832.66
Stockholders' Equity
Common Stock10.2910.298.855.394.494.173.923.553.50
Retained Earnings-562.57-474.04-431.89-263.26-222.97-184.22-152.00-133.78-116.43
Accumulated Other Comprehensive Income-2.98-11.78-10.7353.2742.6735.3830.84165.28165.28
Additional Paid-in Capital617.56609.56455.77226.67184.33153.73138.150.000.00
Shares Outstanding141.70141.67118.85107.8189.780.000.000.000.00
Total Stockholders' Equity62.30134.0221.9922.078.539.0620.9135.0652.35
Total Liabilities & Equity131.44202.64119.45107.5096.1985.9746.0838.8955.01

Frequently Asked Questions About Silence Therapeutics Balance Sheet

What is a balance sheet?

A balance sheet shows a company's financial position at a specific point in time. It lists total assets (what the company owns), total liabilities (what it owes), and stockholders' equity (the difference). The fundamental equation: Assets = Liabilities + Equity.

What is stockholders' equity?

Stockholders' equity represents the net value belonging to shareholders — total assets minus total liabilities. It includes retained earnings, common stock, and additional paid-in capital. Growing equity over time typically indicates a healthy, profitable business.

What is working capital?

Working capital is current assets minus current liabilities. It measures a company's ability to pay short-term obligations with short-term assets. Positive working capital indicates the company can cover its near-term debts; negative may signal liquidity risk.

What is SLN's debt level?

Review Silence Therapeutics's total long-term debt and short-term borrowings in the balance sheet table above. Compare debt to equity and total assets to assess leverage and financial risk.

What is book value per share?

Book value per share is total stockholders' equity divided by shares outstanding. It represents the accounting value per share if the company were liquidated. Comparing market price to book value gives the price-to-book (P/B) ratio — a key valuation metric.

These financial metrics are calculated using balance sheet data. Learn how each metric works and screen stocks by them.